EUVIMEDEUVIMED entdecken
Open Access

IDH wild-type glioblastoma: Predictive value of standard-of-care (SOC) MRI for establishing MGMT promoter methylation status

Kamand Khalaj iD, Elham Tavakkol, Luis Nunez iD, Jordan Jafarnia, Antonio Dono, Octavio Arevalo, Andres Rodriguez, Jay-Jiguang Zhu, Yoshua Esquenazi, Roy Riascos, David Timaran-Montenegro

The Neuroradiology Journal · 2026

DOI: 10.1177/19714009251365745 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Neuroradiology Journal, 2026. Verfasst von Kamand Khalaj und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic and Interventional Imaging, McGovern Medical School, UTHealth Houston, USA. Hauptthemen laut MEDLINE: Glioblastoma, Magnetic Resonance Imaging, Brain Neoplasms, DNA Methylation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Cancer Prevention and Research Institute of Texas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Oxygen 6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is associated with better chemotherapy response and prognosis in glioblastoma patients. This study evaluates the prognostic value of routine MRI findings at initial diagnosis to determine MGMT promoter methylation status.

Methods

A retrospective study was performed on 85 patients with histologically confirmed IDH wild-type glioblastoma. Patients were divided into two groups based on MGMT promoter status: methylated (33 [38.8%]) and unmethylated (52 [61.1%]). MRI findings were assessed using the Visually Accessible Rembrandt Imaging lexicon, and variables were analyzed using univariate analysis (X 2 /Fisher’s test) and logistic regression for independent predictors of MGMT promoter methylation.

Results

A thick enhancing tumoral margin (≥3 mm) was present in 67.3% of MGMT unmethylated glioblastomas and 32.7% of MGMT promoter methylated glioblastomas ( p = .05). Tumoral cortical extension was observed in 68.7% of unmethylated cases versus 31.3% in methylated cases ( p = .01). Non-enhancing tumors were predominantly MGMT methylated (83.3%). In multivariate analysis, tumoral cortical involvement and non-enhancing tumors were independent predictors of MGMT promoter methylation. In survival analysis, higher progression-free survival rates were identified in patients with MGMT promoter methylation ( p = .05) and in patients without cortical tumoral extension ( p = .05).

Conclusion

Our study suggests that while the predictive power of the assessed parameters is modest, thick enhancing tumoral margins and cortical tumor extension were more frequently identified in MGMT unmethylated glioblastomas. Conversely, 83.3% of non-enhancing tumors showed MGMT promoter methylation. Furthermore, MGMT promoter methylation and cortical extension were associated with progression-free survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaMagnetic Resonance ImagingBrain NeoplasmsDNA MethylationDNA Repair EnzymesDNA Modification MethylasesTumor Suppressor ProteinsHumansFemaleMaleMiddle AgedRetrospective StudiesPromoter Regions, GeneticAgedAdultPredictive Value of TestsPrognosisStandard of CareIsocitrate Dehydrogenase

Stichwörter der Autor:innen

GBMMGMT promother methylationVASARIstandard-of-care MRI

Substanzen

DNA Repair EnzymesDNA Modification MethylasesTumor Suppressor ProteinsMGMT protein, humanIsocitrate Dehydrogenase

Autor:innen und Institutionen

  • Department of Diagnostic and Interventional Imaging, McGovern Medical School, UTHealth Houston, USA.
  • Department of Radiology, University of Arkansas for Medical Sciences, USA.
  • Vivian L. Smith Department of Neurosurgery, McGovern Medical School Houston, University of Texas Health Science Center at Houston, , USA.
  • Department of Radiology, Louisiana State University at Shreveport, USA.

ORCID-Profile: Kamand Khalaj, Luis Nunez

Förderung

  • Cancer Prevention and Research Institute of Texas

Zitieren

APA

Khalaj, K., Tavakkol, E., Nunez, L., Jafarnia, J., Dono, A., Arevalo, O., Rodriguez, A., Zhu, J. J., Esquenazi, Y., Riascos, R., & Timaran-Montenegro, D. (2026). IDH wild-type glioblastoma: Predictive value of standard-of-care (SOC) MRI for establishing MGMT promoter methylation status. The Neuroradiology Journal. https://doi.org/10.1177/19714009251365745

Vancouver

Khalaj K, Tavakkol E, Nunez L, Jafarnia J, Dono A, Arevalo O, et al. IDH wild-type glioblastoma: Predictive value of standard-of-care (SOC) MRI for establishing MGMT promoter methylation status. The Neuroradiology Journal. 2026. doi:10.1177/19714009251365745

BibTeX
@article{Khalaj2026,
  author = {Khalaj, Kamand and Tavakkol, Elham and Nunez, Luis and Jafarnia, Jordan and Dono, Antonio and Arevalo, Octavio and Rodriguez, Andres and Zhu, Jay-Jiguang and Esquenazi, Yoshua and Riascos, Roy and Timaran-Montenegro, David},
  title = {IDH wild-type glioblastoma: Predictive value of standard-of-care (SOC) MRI for establishing MGMT promoter methylation status},
  journal = {The Neuroradiology Journal},
  year = {2026},
  doi = {10.1177/19714009251365745}
}
Kostenlos starten →